These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 34140789)

  • 1. US Budget Impact Model for Selinexor, Bortezomib, and Dexamethasone for the Treatment of Previously Treated Multiple Myeloma.
    Dolph M; Tremblay G; Leong H
    Clinicoecon Outcomes Res; 2021; 13():493-502. PubMed ID: 34140789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. US Budget Impact Model for Selinexor in Relapsed or Refractory Multiple Myeloma.
    Bassali J; Gould IG; Kaye JA; Mladsi D; Mehta J
    Clinicoecon Outcomes Res; 2020; 12():317-325. PubMed ID: 32606848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON Trial.
    Dolph M; Tremblay G; Leong H
    Pharmacoeconomics; 2021 Nov; 39(11):1309-1325. PubMed ID: 34368938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma.
    Dolph M; Tremblay G; Gilligan AM; Leong H
    J Health Econ Outcomes Res; 2021; 8(2):26-35. PubMed ID: 34616855
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
    Mateos MV; Gavriatopoulou M; Facon T; Auner HW; Leleu X; Hájek R; Dimopoulos MA; Delimpasi S; Simonova M; Špička I; Pour L; Kriachok I; Pylypenko H; Doronin V; Usenko G; Benjamin R; Dolai TK; Sinha DK; Venner CP; Garg M; Stevens DA; Quach H; Jagannath S; Moreau P; Levy M; Badros AZ; Anderson LD; Bahlis NJ; Cavo M; Chai Y; Jeha J; Arazy M; Shah J; Shacham S; Kauffman MG; Richardson PG; Grosicki S
    J Hematol Oncol; 2021 Apr; 14(1):59. PubMed ID: 33849608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimating the Economic Impact of Adding Panobinostat to a U.S. Formulary for Relapsed and/or Refractory Multiple Myeloma: A Budget Impact and Cost-Benefit Model.
    Bloudek L; Roy A; Kish JK; Siegel DS; Jagannath S; Globe D; Orloski L; Kuriakose ET
    J Manag Care Spec Pharm; 2016 Aug; 22(8):991-1002. PubMed ID: 27459662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States.
    Shah A; Tosh JC; Ambavane A; Nikolaou A; Hogea C; Samyshkin Y; Gorsh B; Maiese EM; Wang F
    Clinicoecon Outcomes Res; 2021; 13():789-800. PubMed ID: 34531667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Budget impact of dostarlimab plus carboplatin-paclitaxel for primary advanced or recurrent endometrial cancer from a third-party US payer perspective.
    Lubinga SJ; Walder L; Burton M; Shen Q
    J Med Econ; 2024; 27(1):1212-1221. PubMed ID: 39254489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk.
    Richard S; Chari A; Delimpasi S; Simonova M; Spicka I; Pour L; Kriachok I; Dimopoulos MA; Pylypenko H; Auner HW; Leleu X; Usenko G; Hajek R; Benjamin R; Dolai TK; Sinha DK; Venner CP; Garg M; Stevens DA; Quach H; Jagannath S; Moreau P; Levy M; Badros A; Anderson LD; Bahlis NJ; Facon T; Mateos MV; Cavo M; Chang H; Landesman Y; Chai Y; Arazy M; Shah J; Shacham S; Kauffman MG; Grosicki S; Richardson PG
    Am J Hematol; 2021 Sep; 96(9):1120-1130. PubMed ID: 34062004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Budget impact analysis of introducing fruquintinib for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy and biologics in the United States from the payer perspective.
    Paly VF; Li S; Khanduri P; Asfaw AA; Zou D; Hernandez L
    J Med Econ; 2024; 27(1):1076-1085. PubMed ID: 39102473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated budget impact model to estimate the impact of introducing selpercatinib as a tumor-agnostic treatment option for patients with
    Bhandari NR; Gilligan AM; Myers J; Ale-Ali A; Smolen L
    J Med Econ; 2024; 27(1):348-358. PubMed ID: 38334069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
    Auner HW; Gavriatopoulou M; Delimpasi S; Simonova M; Spicka I; Pour L; Dimopoulos MA; Kriachok I; Pylypenko H; Leleu X; Doronin V; Usenko G; Hajek R; Benjamin R; Dolai TK; Sinha DK; Venner CP; Garg M; Stevens DA; Quach H; Jagannath S; Moreau P; Levy M; Badros A; Anderson LD; Bahlis NJ; Facon T; Mateos MV; Cavo M; Chai Y; Arazy M; Shah J; Shacham S; Kauffman MG; Richardson PG; Grosicki S
    Am J Hematol; 2021 Jun; 96(6):708-718. PubMed ID: 33755235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Budget Impact Analysis of Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US.
    Ghanem B; Shi L
    Clin Drug Investig; 2022 Dec; 42(12):1085-1092. PubMed ID: 36316586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Case Report of a 58-Year-Old Woman with a Diagnosis of High-Risk Myeloma Refractory to Multiple Line of Therapy and Treated with Selinexor, Bortezomib, and Dexamethasone Prior to Allogeneic Stem Cell Transplantation.
    Cass M; McDonald AB; Ben-Shahar O; Landesman Y; Kashyap T
    Am J Case Rep; 2022 Apr; 23():e935353. PubMed ID: 35444159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Budget Impact of Including Necitumumab on the Formulary for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer: U.S. Commercial Payer and Medicare Perspectives.
    Bly CA; Molife C; Brown J; Tawney MK; Carter GC; Cinfio FN; Klein RW
    J Manag Care Spec Pharm; 2018 Jun; 24(6):534-543. PubMed ID: 29799326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Budget Impact Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) for Preventing Recurrent Clostridioides difficile Infection in the US.
    Lodise T; Guo A; Yang M; Cook EE; Song W; Yang D; Wang Q; Zhao A; Bochan M
    Adv Ther; 2023 Jun; 40(6):2801-2819. PubMed ID: 37093360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Budget impact analysis of venetoclax for the management of acute myeloid leukemia from the perspective of the social security and the private sector in Argentina.
    Palacios A; Espinola N; Gonzalez JM; Rojas-Roque C; Rivas MM; Kanevski D; Morisset P; Augustovski F; Pichon-Riviere A; Bardach A
    PLoS One; 2024; 19(1):e0295798. PubMed ID: 38175833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder.
    Perk S; Wielage RC; Campbell NL; Klein TM; Perkins A; Posta LM; Yuran T; Klein RW; Ng DB
    J Manag Care Spec Pharm; 2016 Sep; 22(9):1072-84. PubMed ID: 27579830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Budget Impact Analysis of the FreeStyle Libre Flash Continuous Glucose Monitoring System
    Palacios A; Rodriguez-Cairoli F; Balan D; Rojas-Roque C; Moreno-López C; Braun B; Augustovski F; Pichon-Riviere A; Bardach A
    Appl Health Econ Health Policy; 2023 Jul; 21(4):637-650. PubMed ID: 37062046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selinexor in Patients from Argentina with Multiple Myeloma Treated with Multiple Prior Therapies: A Case Series.
    Remaggi G; Ochoa PA; Garate GM
    Am J Case Rep; 2022 Jul; 23():e936505. PubMed ID: 35834427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.